In 2017, an estimated 10.0 million people had active tuberculosis (TB), and 1.6 million TB-related deaths were recorded worldwide \[[@CIT0001]\]. Tuberculosis remains the most common infectious disease in the world \[[@CIT0002]\]. In the last decade, TB prevention has followed the Global Plan To Stop TB 2006--2015, which aims to reduce TB incidence and deaths \[[@CIT0003]\]. After the goal was almost reached in 2015, the World Health Organization (WHO) suggested the END TB Strategy for the post-2015 era, including controlling latent TB infection (LTBI) towards TB elimination \[[@CIT0004]\]. Among the strategies, we need to screen high-risk groups for LTBI treatment to prevent TB occurrence and transmission \[[@CIT0005]\]. According to the WHO, 2 such high-risk groups are kidney transplantation candidates (KTCs) and kidney transplantation recipients (KTRs) \[[@CIT0005]\].

In fact, patients with solid organ transplantation have been reported to have TB incidence as high as 506--512 per 100 000 person-years in China and Spain, respectively, which is appproximately 7--27 times higher than that of the general population \[[@CIT0006], [@CIT0007]\]. In particular, kidney transplantation has an odds ratio (OR) of 4.59 for developing TB \[[@CIT0008]\]. In addition, preoperative LTBI has been identified as a risk factor for developing TB \[[@CIT0008]\]. Once TB develops in patients with kidney transplantation, morbidity is high, approximately 6.1--8.9% \[[@CIT0006], [@CIT0007], [@CIT0009], [@CIT0010]\], and TB may cause loss of the renal allograft \[[@CIT0011]\] because the manifestations of TB are atypical and delayed diagnosis ensues \[[@CIT0009], [@CIT0010]\]. Therefore, LTBI and TB are clinical concerns for patients belonging to the KTC and KTR groups.

Active TB can develop in patients after kidney transplantation from different pathogenesis, including reactivation from LTBI before or a new infection after transplantation \[[@CIT0012]\], which increases due to immunosuppressive therapy. The WHO suggests that clinicians screen and manage LTBI before transplantation to reduce the possibility of reactivation \[[@CIT0013]\]. Under the LTBI intervention strategy, the problem that remains after we have treated pre-existing LTBI is new infection or the reactivation of immune-unrecognized *Mycobacterium tuberculosis* after kidney transplantation. However, the prevalence of LTBI and its incidence trend after kidney transplantation remain unclear. Only a few cross-sectional studies have evaluated LTBI prevalence in KTRs \[[@CIT0014], [@CIT0015]\], and we have limited knowledge of new *M. tuberculosis* infection in this targeted population. Therefore, we conducted this study to evaluate the status of LTBI in patients after kidney transplantation in order to provide information for future TB-control consensus.

METHODS {#s1}
=======

Participant Enrollment {#s2}
----------------------

This prospective study was conducted in a tertiary referral medical center in northern Taiwan. Under the approval of the Research Ethics Committee of the study hospital (no. 201309056RINC), we recruited patients aged 20 years or older who were KTCs or KTRs in transplantation clinics from January 2014 to December 2018. All of the final enrolled participants provided signed informed-consent forms. We excluded patients with active TB, prior history of TB, liver cirrhosis, active cancer, and human immunodeficiency virus infection ([Figure 1](#F1){ref-type="fig"}).

![Flow chart of participant enrollment. Abbreviations: QFT, QuantiFERON-TB Gold In-tube; TB, tuberculosis.](ciz851f0001){#F1}

Tuberculosis and Latent Tuberculosis Infection Definitions {#s3}
----------------------------------------------------------

Each participant's clinical history, symptoms, and chest radiograph were reviewed to exclude active TB disease \[[@CIT0016]\]. Mycobacterial study of 3 sputum samples and computerized tomography were arranged if active TB was suspected \[[@CIT0017]\]. Active TB was defined as microbiology positive for *M. tuberculosis* or typical pathology or radiographic findings if available. After excluding cases of active TB, we sampled each participant's peripheral blood and examined a QuantiFERON-TB Gold In-Tube assay (QFT) (Cellestis, Australia) using a 3-tube kit \[[@CIT0018]\]. Interferon-γ level was measured in the reaction supernatants, and the results were interpreted as positive, negative, or indeterminate according to the manufacturer's recommendation \[[@CIT0019], [@CIT0020]\]. In this study, LTBI was defined as a positive QFT result. We then compared the prevalence of LTBI status between the KTR and KTC groups.

For patients with initial negative QFT, we followed up the QFT status every 6 months for 2 years. We categorized the positive conversion of QFT as new LTBI and stopped further follow-up. If a KTC with negative QFT received transplantation, he or she was transferred from the KTC group to the new KTR group for follow-up. For those without a pretransplantation test of QFT, we tested their LTBI status within 3 months after kidney transplantation and followed up with them if the QFT result was negative. The overall incidence rates of new LTBI were calculated for the KTC group, overall KTR group, and new KTR group.

For patients with positive QFT, we suggested preventive therapy if there were no contraindications. The acceptance rate of the therapy was not 100% because it was not a mandatory component of standard care in Taiwan. We followed up all participants for 2 years and checked for the occurrence of active TB in the Taiwan TB Registry.

Data Collection {#s4}
---------------

The demographic and clinical data, including age, gender, underlying comorbidities, details of dialysis or transplantation, prior TB history, laboratory results, and immunosuppressants, were reviewed from the hospital's electronic records. Trained assistants and investigators interviewed the participants for respiratory and constitutional symptoms, smoking status, and history of TB exposure with a questionnaire. Body mass index (BMI) and scar number for bacillus Calmette--Guérin (BCG) vaccination were checked by trained assistants.

For the KTR group, we recorded the data of the transplants, including living or deceased donor, the presence of donor-specific antibody (DSA), ABO blood type-incompatible (ABO incompatible) status of the donor, usage of induction therapy, and maintenance immunosuppressant drugs. We recorded induction therapy and the kinds of maintenance immunosuppressant drugs, especially during the examination of baseline QFT. The usual maintenance immunosuppressive regimen comprised tacrolimus with mycophenolate mofetil and steroids. We used rituximab plus plasmapheresis as the induction therapy for kidney transplantation with positive DSA (DSA+) \[[@CIT0021]\] or ABO-incompatible donors \[[@CIT0022]\]. For recipients with positive DSA, intravenous immunoglobulin (IVIG) infusion after plasmapheresis was given for desensitization \[[@CIT0021]\].

Chest radiography and computerized tomography were interpreted independently by a pulmonologist and a radiologist \[[@CIT0023]\]. If the interpretations by the 2 readers differed, we consulted a senior pulmonologist to discuss the final coding. The classifications of radiographic findings are detailed in the [Supplementary File](#sup1){ref-type="supplementary-material"}.

Statistical Analysis {#s5}
--------------------

Intergroup differences were analyzed using the Student's *t* test for numerical variables, as appropriate, and chi-square test for categorical variables. Multivariate logistic regression analysis was used to identify factors associated with baseline LTBI using the stepwise method. (The details of factor selection are provided in the [Supplementary File](#sup1){ref-type="supplementary-material"}). A 2-sided *P* \< .05 was considered significant. All analyses were performed in SPSS (version 19.0; IBM Corporation).

RESULTS {#s6}
=======

Participant Recruitment and Demographics {#s7}
----------------------------------------

During the study period, 489 participants were recruited. Among them, 17 were excluded due to prior TB and 47 withdrew their consent. Finally, 425 patients received QFT examinations. Among them, 305 patients belonged to the KTC group and the other 120 patients were in the KTR group ([Figure 1](#F1){ref-type="fig"}).

With regard to demographic characteristics ([Table 1](#T1){ref-type="table"}), the average age between the 2 groups was similar (47.5 vs 48.9 years, *P* = .217), but the proportion of males was higher (60% vs 48%, *P* = .034) in the KTC group than in the KTR group. In addition, the presence of underlying diabetes mellitus and congestive heart failure was higher in the KTC group, whereas hepatitis B virus infection and rheumatoid arthritis were higher in the KTR group. Laboratory data showed lower blood hemoglobin and total bilirubin but higher blood leukocyte counts in the KTC group than in the KTR group. There were no differences regarding other TB-associated clinical factors, such as smoking, scar of BCG vaccination, BMI, TB exposure, and dialysis history. The presence of any respiratory symptoms and radiographic lesions as well as the values of the initial QFT response were similar between the 2 groups.

###### 

Baseline Clinical Characteristics of the Kidney Transplantation Candidates and Kidney Transplantation Recipients

                                    KTCs (n = 305)   KTRs (n = 120)   *P*
  --------------------------------- ---------------- ---------------- --------
  Age, year                         47.5 ± 10.9      48.9 ± 11.9      .217
  Male gender                       182 (60)         58 (48)          .034
  Smoking                                                             .320
  ** **Current                      24 (8)           5 (4)            
  ** **Former                       48 (16)          18 (15)          
  BMI, kg/m^2^                      23.4 ± 4.4       23.1 ± 3.6       .473
  BCG scar^a^                                                         .900
  ** **0                            11 (4)           4 (3)            
  ** **1                            220 (73)         85 (71)          
  ** **≥2                           72 (24)          31 (26)          
  History of TB exposure            22 (7)           4 (3)            .133
  Dialysis^b^                                                         
  ** **Dialysis duration, years     4.3 ± 5.2        4.1 ± 4.3        .745
  ** **Mode: HD                     175 (57)         ...              
  ** **Mode: PD                     123 (40)         ...              
  Diabetes mellitus, presence                                         .043
  ** **Diet control                 6 (2)            0                
  ** **OAD use                      36 (12)          6 (5)            
  ** **Insulin use                  12 (4)           8 (7)            
  Cardiovascular disease                                              
  ** **CAD                          31 (10)          6 (5)            .089
  ** **CHF                          22 (7)           1 (1)            .009
  Liver disorder                                                      
  ** **HBV                          17 (6)           14 (12)          .030
  ** **HCV                          7 (2)            1 (1)            .318
  Autoimmune disease                                                  
  ** **RA                           0                2 (2)            .024
  ** **SLE                          13 (4)           6 (5)            .740
  Previous kidney transplantation   11 (4)           2 (2)            .296
  COPD                              2 (1)            2 (2)            .331
  Any radiological lesion                                             .337
  ** **Not compatible with TB       68 (22)          31 (26)          
  ** **Compatible with prior TB     10 (3)           3 (3)            
  Presence of symptoms^c^           84 (28)          25 (21)          .154
  Leukocytes, cells/mm^3^           7086 ± 2341      6590 ± 1931      .026
  Hemoglobin, g/dL                  10.8 ± 1.8       12.9 ± 2.3       \<.001
  Albumin,^a^ g/dL                  4.2 ± 0.5        4.3 ± 0.4        .072
  Total bilirubin,^a^ mg/dL         0.45 ± 0.15      0.59 ± 0.22      \<.001
  First QFT response, /mL                                             
  ** **TB tube--Nil tube            0.21 ± 0.87      0.21 ± 0.58      .887
  ** **Mitogen tube                 6.66 ± 3.64      6.03 ± 4.01      .138

Data are presented as no. (%) or mean ± standard deviation.

Abbreviations: BCG, bacillus Calmette--Guérin vaccination; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; HD, hemodialysis; KTC, kidney transplantation candidate; KTR, kidney transplantation recipient; Nil tube, negative control tube or NC tube; OAD, oral antidiabetic agent; PD, peritoneal dialysis; QFT, QuantiFERON-TB Gold In-tube; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis.

^a^Data missing in 2 for BCG, 11 for albumin, and 26 for total bilirubin.

^b^Dialysis indicates current dialysis status of the KTC group but pretransplantation status of the KTR group. There were 7 KTCs who did not receive dialysis.

^c^Indicates chronic cough, dyspnea, and other constitutional symptoms.

Details of Initial Latent Tuberculosis Infection Status {#s8}
-------------------------------------------------------

In the initial QFT examination, positive results were reported in 32 (10.5%) patients in the KTC group and 24 (20.0%) patients in the KTR group ([Figure 1](#F1){ref-type="fig"}). The positive rate of QFT was significantly higher in the KTR group (*P* = .009 by chi-square test) than in the KTC group. Among the patients with positive initial QFT, 13 (54%) in the KTR group and 20 (63%) in the KTC group received preventive therapy for LTBI (*P* = .530). The remaining patients with LTBI requested observation and declined preventive LTBI treatment. The QFT response value in LTBI treatment recipients was 1.20 ± 1.10 IU/mL, which was similar to the response value of 1.89 ± 2.19 in those without treatment (*P* = .174). Although indeterminate results were also higher in the KTR group than in the KTC group, the difference was not significant (10% vs 5.9%, *P* = .138). With regard to the QFT response value, the response was higher in the KTR group with positive initial QFT results than in the KTC group (1.85 ± 2.01 vs 1.06 ± 0.82, *P* = .046). For those with initial negative or indeterminate results, the values were similar in the 2 groups.

Factors Associated With Baseline Latent Tuberculosis Infection {#s9}
--------------------------------------------------------------

To further differentiate factors associated with baseline LTBI in all of the study participants, we performed logistic regression. Increasing age, coronary artery disease (CAD), hepatitis B virus infection, scar of BCG vaccination, positive DSA, induction therapy, and kidney transplantation were significant factors in the univariate analysis ([Table 2](#T2){ref-type="table"}). Multivariate logistic regression by a stepwise method was performed by using all significant factors in univariate analysis and other relevant factors, such as gender and TB exposure. The results showed that the positive independent factors for LTBI included increasing age (OR, 1.027; 95% confidence interval \[CI\], 1.000--1.055, per 1-year increment; *P* = .050), positive DSA (OR, 8.242; 95% CI, 1.249--54.399; *P* = .028), and receiving kidney transplantation (OR, 1.904; 95% CI, 1.031--3.516; *P* = .040), whereas the negative factor was BCG vaccination (OR \[95% CI\], 0.199 \[.065--.608\] \[*P* = .005\] for 1 scar and 0.175 \[.051--.598\] \[*P* = .005\] for 2 scars compared with no vaccination scar).

###### 

Univariate and Multivariate Logistic Regression for Predicting Positive Interferon-γ Release Assay Among Patients

  Characteristics                          Univariate                     Multivariate            
  ---------------------------------------- ----------------------- ------ ----------------------- ------
  Age, years                               1.028 (1.001--1.055)    .046   1.027 (1.000--1.055)    .050
  Gender, male vs female                   1.333 (.748--2.378)     .330   ...                     
  Current smoker vs others                 1.805 (.701--4.650)     .221   ...                     
  Diabetes mellitus                                                                               
  ** **Absence                             Reference                      ...                     
  ** **Diet control                        1.387 (.158--12.141)    .221   ...                     
  ** **OAD use                             1.156 (.461--2.879)     .221   ...                     
  ** **Insulin use                         1.733 (.555--5.416)     .221   ...                     
  Cardiovascular disease                                                                          
  ** **CAD                                 2.332 (1.037--5.245)    .041   ...                     
  ** **CHF                                 0.287 (.038--2.171)     .226   ...                     
  Liver disorder                                                                                  
  ** **HBV                                 2.507 (1.062--5.921)    .036   ...                     
  ** **HCV                                 2.241 (.441--11.387)    .331   ...                     
  Autoimmune disease                                                                              
  ** **RA                                  N/A                     .999   ...                     
  ** **SLE                                 1.249 (.352--4.431)     .731   ...                     
  Previous kidney transplantation          1.205 (.260--5.587)     .811   ...                     
  COPD                                     N/A                     .999   ...                     
  TB exposure                              0.852 (.247--2.952)     .799   ...                     
  BMI, kg/m^2^                             0.996 (.931--1.065)     .900   ...                     
  BCG scar^a^                                                                                     
  ** **0                                   Reference                      Reference               
  ** **1                                   0.213 (.072--.633)      .005   0.199 (.065--.608)      .005
  ** **≥2                                  0.198 (.060--.654)      .008   0.175 (.051--.598)      .005
  Current dialysis mode                                                                           
  ** **No dialysis                         Reference                      ...                     
  ** **Peritoneal dialysis                 0.637 (.290--1.398)     .260   ...                     
  ** **Hemodialysis                        1.028 (.533--1.982)     .934   ...                     
  KTR compared with KTC group              2.133 (1.196--3.802)    .010   1.904 (1.031--3.516)    .040
  KTR, liver donor vs deceased donor       0.986 (.425--2.284)     .973   ...                     
  Donor, ABO, incompatible vs compatible   3.060 (.910--10.294)    .071   ...                     
  DSA, presence vs absence                 3.214 (1.299--7.954)    .012   8.242 (1.249--54.399)   .028
  Induction therapy, presence vs absence   3.900 (1.257--12.095)   .018   ...                     
  Symptoms,^b^ presence vs none            1.447 (.787--2.660)     .234   ...                     
  Radiologic lesion, any vs none           0.807 (.417--1.564)     .526   ...                     
  Leukocyte count, cells/mm^3^             1.000 (1.000--1.000)    .870   ...                     
  Hemoglobin, g/dL                         1.088 (.966--1.225)     .165   ...                     
  Albumin,^a^ g/dL                         1.268 (.709--2.268)     .423   ...                     
  Total bilirubin,^a^ mg/dL                2.212 (.480--9.380)     .321   ...                     

Abbreviations: ABO, ABO blood types; BCG, bacillus Calmette--Guérin vaccination; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DSA, donor-specific antibody; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; KTC, kidney transplantation candidate; KTR, kidney transplantation recipient; N/A, not applicable, meaning the results were very low; OAD, oral antidiabetic agent; OR, odds ratio; QFT, QuantiFERON-TB Gold In-tube; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis.

^a^Data missing in 2 for BCG, 11 for albumin, and 26 for total bilirubin.

^b^Indicates chronic cough, dyspnea, and other constitutional symptoms.

Within the KTR group ([Table 3](#T3){ref-type="table"}), positive DSA was also significantly associated with LTBI status. Underlying CAD, autoimmune disease, hepatitis C virus infection, prior kidney transplantation history, and presence of respiratory symptoms were associated with LTBI status. Immunosuppressants were not significantly associated with LTBI status.

###### 

Details of Status and Immunosuppressants Among Kidney Transplantation Recipients According to Status of Latent Tuberculosis Infection

                                      All (N = 120)   LTBI (n = 24)   No LTBI (n = 96)   *P*
  ----------------------------------- --------------- --------------- ------------------ ------
  Age, years                          48.9 ± 11.9     51.6 ± 10.7     48.3 ± 12.2        .233
  Male gender                         58 (48)         14 (58)         44 (46)            .273
  Smoking                                                                                .668
  ** **Current                        5 (4)           1 (4)           4 (4)              
  ** **Former                         18 (15)         5 (21)          13 (14)            
  BMI, kg/m^2^                        23.1 ± 3.6      23.4 ± 3.4      23.1 ± 3.7         .711
  BCG scar                                                                               .281
  ** **0                              4 (3)           2 (8)           2 (2)              
  ** **1                              85 (71)         17 (71)         68 (71)            
  ** **≥2                             31 (26)         5 (21)          26 (27)            
  Time after transplantation, years   6.3 ± 5.6       5.0 ± 5.6       6.7 ± 5.6          .177
  Donor                                                                                  
  ** **Living donor                   61 (51)         12 (50)         49 (51)            .927
  ** **DSA^a^                         5 (4)           3 (13)          2 (2)              .024
  ** **ABOi^a^                        11 (9)          3 (11)          8 (9)              .549
  Induction therapy                   14 (12)         5 (21)          9 (10)             .128
  Immunosuppressants, at QFT test                                                        
  ** **Mycophenolate mofetil          64 (53)         14 (58)         50 (52)            .583
  ** **Tacrolimus                     111 (93)        21 (88)         90 (94)            .298
  ** **Everolimus                     11 (9)          0               11 (12)            .082
  ** **Sirolimus                      48 (40)         9 (38)          39 (41)            .780
  ** **Azathioprine                   14 (12)         3 (13)          11 (12)            .887
  ** **Mycophenolic acid              38 (32)         8 (33)          30 (31)            .844
  ** **Cyclosporine                   2 (2)           0               2 (2)              .476
  ** **Prednisolone                   96 (80)         17 (71)         79 (82)            .209
  History of TB exposure              4 (3)           0               4 (4)              .309
  Diabetes mellitus, presence                                                            .289
  ** **Diet control                   0               0               0                  
  ** **OAD use                        6 (5)           2 (8)           4 (4)              
  ** **Insulin use                    8 (7)           3 (13)          5 (5)              
  Cardiovascular disease                                                                 
  ** **CAD                            6 (5)           4 (17)          2 (2)              .003
  ** **CHF                            1 (1)           0               1 (1)              .616
  Liver disorder                                                                         
  ** **HBV                            14 (12)         5 (21)          9 (9)              .118
  ** **HCV                            1 (1)           1 (4)           0                  .045
  Autoimmune disease                                                                     
  ** **Total                          10 (8)          5 (21)          5 (5)              .013
  ** **RA                             2 (2)           2 (8)           0                  .004
  ** **SLE                            6 (5)           3 (13)          3 (3)              .059
  Kidney transplantation before       2 (2)           2 (8)           0                  .004
  COPD                                2 (2)           0               2 (2)              .476
  Any radiological lesion                                                                .337
  ** **Not compatible with TB         31 (26)         5 (21)          26 (27)            
  ** **Compatible with prior TB       3 (3)           1 (4)           2 (2)              
  Presence of symptoms^b^             25 (21)         9 (38)          16 (17)            .025
  Leukocytes, cells/mm^3^             6590 ± 1931     6524 ± 1779     6606 ± 1975        .853
  Hemoglobin, g/dL                    12.9 ± 2.3      12.5 ± 2.6      13.0 ± 2.4         .404
  Albumin, g/dL                       4.3 ± 0.4       4.3 ± 0.4       4.3 ± 0.4          .584
  Total bilirubin, mg/dL              0.59 ± 0.22     0.61 ± 0.20     0.59 ± 0.22        .713

Data are presented as no. (%) or mean ± standard deviation.

Abbreviations: ABOi, ABO blood type-incompatible; BCG, bacillus Calmette--Guérin vaccination; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DSA, donor-specific antibody; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; LTBI, latent tuberculosis infection; OAD, oral antidiabetic agent; QFT, QuantiFERON-TB Gold In-tube; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis.

^a^There were 2 cases with ABOi and DSA together.

^b^Indicated chronic cough, dyspnea, and other constitutional symptoms.

Details of Latent Tuberculosis Infection in the Follow-up Course {#s10}
----------------------------------------------------------------

The participants with initial negative QFT status were invited to be followed up for QFT every 6 months. There were 161 in the KTC group, 51 in the overall KTR group, and 15 in the new KTR group ([Table 4](#T4){ref-type="table"}). The demographic characteristics among those with initial negative LTBI and follow-up were similar, except that the blood hemoglobin and total bilirubin levels were higher but leukocyte counts were lower in the overall KTR group than in the KTC group. With regard to induction therapy, 3 patients received induction therapy before kidney transplantation with incompatible ABO status in the KTR group. Among them, all 3 patients had no LTBI conversion (6.8% vs 0, *P* = .476). All of the cohort reported no TB exposure during the follow-up. The new positive QFT numbers in the 3 groups are shown in [Figure 2A](#F2){ref-type="fig"}. Within the 2-year follow-up, 9 (5.6%), 7 (13.7%), and 3 (20%) patients had QFT positive conversion in the KTC, overall KTR, and new KTR groups, respectively. The positive conversion rate was higher in the new and overall KTR groups than in the KTC group (*P* = .034 and .055, respectively) ([Figure 2B](#F2){ref-type="fig"}).

###### 

Demographic Characteristics of Participants With Initial Negative Result of QuantiFERON-TB Gold In-tube and Receiving Follow-up Using QuantiFERON-TB Gold In-tube

                                                     KTCs (n = 161)   All KTRs (n = 51)   *P*1     New KTRs (n = 15)   *P*2
  -------------------------------------------------- ---------------- ------------------- -------- ------------------- ------
  Age, years                                         47.8 ± 10.9      49.3 ± 10.6         .396     43.9 ± 13.0         .323
  Male gender                                        89 (55)          27 (53)             .830     11 (73)             .175
  Smoking                                                                                 .965                         .944
  ** **Current                                       11 (8)           3 (6)                        1 (7)               
  ** **Former                                        27 (17)          9 (18)                       2 (13)              
  BMI, kg/m^2^                                       23.5 ± 4.7       23.4 ± 4.0          .991     23.4 ± 4.8          .926
  BCG scar                                                                                .324                         .635
  ** **0                                             4 (2)            2 (4)                        1 (7)               
  ** **1                                             116 (72)         31 (61)                      10 (67)             
  ** **≥2                                            41 (26)          18 (35)                      4 (27)              
  History of TB exposure                             11 (7)           3 (6)               .812     1 (7)               .985
  Dialysis duration,^a^ years                        4.3 ± 4.5        4.5 ± 3.8           .473     4.2 ± 3.8           .953
  Living donor (otherwise deceased)                  ...              18 (35)                      7 (47)              
  DSA positive                                       ...              0                            0                   
  ABOi                                               ...              3 (6)                        1 (7)               
  Induction therapy                                  ...              3 (6)                        1 (7)               
  Immunosuppressants, after kidney transplantation                                                                     
  ** **Mycophenolate mofetil                         ...              37 (73)                      13 (87)             
  ** **Tacrolimus                                    ...              45 (88)                      15 (100)            
  ** **Everolimus                                    ...              0                            0                   
  ** **Sirolimus                                     ...              3 (6)                        1 (7)               
  ** **Azathioprine                                  ...              0                            0                   
  ** **Mycophenolic acid                             ...              8 (16)                       2 (13)              
  ** **Cyclosporine                                  ...              5 (10)                       0                   
  ** **Prednisolone                                  ...              50 (98)                      15 (100)            
  Diabetes mellitus                                                                       .457                         .944
  ** **Diet control                                  1 (1)            0                            0                   
  ** **OAD use                                       20 (12)          5 (10)                       2 (13)              
  ** **Insulin use                                   5 (3)            4 (8)                        1 (7)               
  Cardiovascular disease                                                                                               
  ** **CAD                                           12 (7)           3 (6)               .703     2 (13)              .416
  ** **CHF                                           13 (8)           1 (2)               .126     1 (8)               .852
  Liver disorder                                                                                                       
  ** **HBV                                           7 (4)            4 (8)               .327     1 (7)               .676
  ** **HCV                                           2 (1)            0                   .424     0                   .665
  Autoimmune disease                                                                                                   
  ** **Total                                         12 (7)           3 (6)               .703     1 (7)               .916
  ** **SLE                                           11 (7)           2 (4)               .450     1 (7)               .985
  Kidney transplantation before                      8 (5)            0                   .105     0                   .378
  COPD                                               1 (1)            1 (2)               .388     0                   .760
  Any radiological lesion                                                                 .840                         .526
  ** **Not compatible with TB                        38 (24)          13 (26)                      2 (14)              
  ** **Compatible with prior TB                      6 (4)            1 (2)                        0                   
  Presence of symptoms^b^                            57 (35)          11 (22)             .065     3 (20)              .224
  Leukocytes, cells/mm^3^                            7139 ± 2399      6026 ± 1739         .002     6255 ± 2062         .165
  Hemoglobin, g/dL                                   10.9 ± 1.7       12.8 ± 2.4          \<.001   12.0 ± 2.4          .148
  Albumin, g/dL                                      4.2 ± 0.5        4.2 ± 0.5           .764     4.1 ± 0.7           .227
  Total bilirubin, mg/dL                             0.44 ± 0.12      0.58 ± 0.20         \<.001   0.49 ± 0.17         .520

Data are presented as no. (%) or mean ± standard deviation. Patients are classified by transplantation status. *P*1 and *P*2 values are compared between all patients with kidney transplantation vs waiting group and patients with new kidney transplantation vs waiting group, respectively.

Abbreviations: ABOi, ABO blood type-incompatible; BCG, bacillus Calmette--Guérin vaccination; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DSA, donor-specific antibody; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; KTC, kidney transplantation candidate; KTR, kidney transplantation recipient; OAD, oral antidiabetic agent; QFT, QuantiFERON-TB Gold In-tube; SLE, systemic lupus erythematosus; TB, tuberculosis.

^a^Dialysis indicates current dialysis status of KTC group but pretransplantation status of KTR group.

^b^Indicates chronic cough, dyspnea, and other constitutional symptoms.

![The follow-up results of QFT for participants with initial negative QFT according to kidney transplantation status. *A*, The new positive QFT number. *B*, The percentage of positive conversion. Abbreviations: KTC, kidney transplantation candidate; KTR, kidney transplantation recipient; m, months; QFT, QuantiFERON-TB Gold In-tube.](ciz851f0002){#F2}

Among those who underwent kidney transplantation, 2 cases had active TB development. The first patient received kidney transplantation from a deceased donor. His maintenance immunosuppressants included tacrolimus, mycophenolate mofetil, and prednisolone. His initial QFT was positive, but no preventive therapy was given because the patient refused it. Active pulmonary TB was diagnosed by suspicious findings on radiography plus treatment response at approximately 11.5 months after kidney transplantation. He was treated with an anti-TB regimen with good graft function. The other patient, who had hepatitis C virus infection, had received a deceased-donor kidney transplantation 27 years before the initial negative QFT. The maintenance immunosuppressants were cyclosporine, mycophenolate mofetil, and prednisolone. During our follow-up, his kidney function declined, and he received a second renal transplantation from a deceased donor at the 22nd month of follow-up. He had chronic cough and QFT at the 24th month, indicating positive conversion. Pulmonary TB was diagnosed by positive sputum acid-fast smear and mycobacterial culture for *M. tuberculosis*. The treatment course for TB was uneventful, without major drug adverse effects. The incidence of TB was approximately 833 per 100 000 person-years (2 in 120 cases with kidney transplantation in 2 years). In contrast, no active TB cases developed in the KTC group during the 2-year follow-up.

DISCUSSION {#s11}
==========

In the present study, we report that KTRs had a higher LTBI prevalence and incidence than KTCs in a cross-sectional and cohort study design, respectively. For this population, old age, absence of BCG vaccination scar, and positive DSA, in addition to receiving a kidney transplantation, were significant factors associated with positive QFT-defined LTBI.

In the post-2015 era, the WHO aims to eliminate TB worldwide and has established many frameworks \[[@CIT0004]\]. Among them, LTBI screening and treatment are vitally important issues \[[@CIT0005]\] and have been recommended in high- or intermediate-income countries with a TB incidence of less than 100 per 100 000 person-years \[[@CIT0013]\]. Of the LTBI-risk population, patients with kidney transplantation account for a major proportion of transplantation patients \[[@CIT0024]\] and need to be targeted because of their immunocompromised status and high mortality once active TB develops. Under contemporary recommendations, pretransplantation LTBI screening has been implemented worldwide \[[@CIT0007], [@CIT0025]\]; however, no evidence of LTBI survey after transplantation has been reported before this prospective study.

The present cross-sectional study found a higher LTBI prevalence in the KTR group than in the KTC group, which was supported by adjustment of the multivariate analysis. In addition, the occurrence of new LTBI infection and active TB development within 2 years was also higher in the KTR group than in the KTC group. These facts emphasize the importance of LTBI/TB control after kidney transplantation. Among the factors associated with LTBI status after kidney transplantation, positive DSA was an independent factor. The process and medication given before transplantation with positive DSA included induction with rituximab and IVIG infusion after plasmapheresis for desensitization \[[@CIT0021]\]. In comparison with incompatible ABO status, IVIG was the only additional medication in recipients with positive DSA. Therefore, we suggest that IVIG-related suppression of T cells \[[@CIT0026]\] and innate immune cells \[[@CIT0027]\] might be an important factor that leads to susceptibility to *M. tuberculosis* infection. In addition, the status of kidney transplantation was still one of the independent predictors for LTBI ([Table 2](#T2){ref-type="table"}). Kidney transplantation status might be a surrogate of many complex factors after transplantation, one which cannot be dissected with the scale of the current study and the collinearity between transplantation status and immunosuppressant medications. Although the procedure of induction therapy and the immunosuppressants might be important concerns related to LTBI status, no statistical significance was found in this study. Further large-scale studies focusing on the effects of medication are required.

The higher rate of positive conversion among the new KTR group might have arisen because some of them had false-negative QFT prior to transplantation due to dormant status or a long interval since *M. tuberculosis* infection \[[@CIT0028]\]. This kind of activation of dormant or immune-unrecognized *M. tuberculosis* might be the pathogenesis of positive conversion of LTBI soon after recent kidney transplantation with the use of immunosuppressants. On the other hand, a new *M. tuberculosis* infection could exist among the KTR or KTC group \[[@CIT0029]\]. However, the susceptibility to new *M. tuberculosis* infection might be higher in the KTR group than in the KTC population ([Figure 2B](#F2){ref-type="fig"}), possibly due to the process and immunosuppression therapy used for the transplantation \[[@CIT0030], [@CIT0031]\]. The QFT conversion rates in the KTR groups were similar, with 7--8.5% conversion at the 12-month follow-up \[[@CIT0032], [@CIT0033]\] and 13.6% conversion at the 24-month follow-up \[[@CIT0034]\] among patients with rheumatoid disease receiving biologic agents. Therefore, this result indicates that, in addition to pretransplantation screening, surveillance of LTBI is also needed after transplantation. Although the duration of follow-up remains unclear and requires further investigation, we propose LTBI checks at least twice annually after transplantation because the highest risk of LTBI conversion occurs approximately 6--12 months after kidney transplantation, and active TB occurs more frequently within the first 2 years, according to the literature and our report \[[@CIT0006], [@CIT0035]\]. We have no suggestions for periods exceeding 2 years due to limited data. In addition, data may need to be collected in an area with less TB prevalence.

On the other hand, many clinical factors in addition to kidney transplantation favored positive LTBI status. Among them, age is a well-known factor that is positively correlated with the QFT-positive rate \[[@CIT0036]\]. In contrast, a present BCG vaccination scar shows a negative correlation with LTBI, which is consistent with investigations in children \[[@CIT0037]\] and adult prisoners \[[@CIT0038]\]. With regard to TB exposure, the association with positive QFT is not significant and may be related to the information not being recent and having been collected by questionnaire. Therefore, the effect and significance might be less correlated than in a previous report on TB contact \[[@CIT0039]\].

There are several limitations to the present study. First, the participants were voluntarily enrolled, so selection bias might exist. Second, the use of questionnaires for some data collection, such as TB exposure and smoking, might have incurred recall bias. Third, the case number for the 2-year follow-up was small. A validation study is needed. Fourth, the QFT statuses of the living donors were not checked. Last, the participants were enrolled in Taiwan, so generalization to other areas or ethnicities may not be applicable and will require further study.

In conclusion, LTBI was higher in the KTR group than in the KTC group. Old age, absent BCG scar, positive DSA, and status of kidney transplantation were LTBI-associated factors. In particular, the prevalence of positive LTBI conversion was approximately 20% within 2 years in the new KTR group. This finding indicated that a strategy for posttransplantation LTBI surveillance is needed, despite this not being included in current LTBI recommendations.

Supplementary Data {#s12}
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Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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